BioSpace News Archive

Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody candidate that was generated through a research collaboration between the two companies initiated in 2017.

Selvita S.A. one of the largest preclinical contract research organizations in Europe, continues its dynamic development in Poland and abroad.

Novavax, Inc. announced submission of its request to expand the conditional marketing authorization of Nuvaxovid™ COVID-19 Vaccine in the European Union to adolescents aged 12 through 17 years.

Rune Labs, a precision neurology software and data platform company, today announced the addition of Mark Dresser , PhD, to its scientific advisory board.

Brii Biosciences Limited presented new data from a Phase 2 randomized, double-blind, placebo-controlled trial of BRII-835 in Chinese patients with chronic hepatitis B virus infection, at the 31st Conference of Asian Pacific Association for the Study of the Liver 2022, taking place virtually from March 30 to April 3 in Seoul, South Korea.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced an upcoming oral presentation and three poster presentations at the American Academy of Neurology Annual Meeting, which will take place in Seattle April 2-7, 2022 and virtually April 24-26, 2022.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the year ended December 31, 2021, and provided an update on clinical and corporate progress.

Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2021 and provided a business update on recent corporate and clinical developments.

BD, a leading global medical technology company, announced that Alberto Mas has informed the company of his intent to retire from BD, effective at the end of the company’s fiscal year on Sept. 30, 2022.

BioNTech SE announced that it has entered into a share repurchase program, pursuant to which the Company may purchase American depositary shares in the amount of up to $1.5 billion over the next two years.